NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)

This trial tests whether an oral herbal supplement called LCS103 can help prevent non-muscle invasive bladder cancer from recurring after surgery. Sixty adults who have had their bladder tumors completely removed will take either LCS103 plus standard care or standard care alone f…

This phase II trial is testing a combination of two drugs—disitamab vedotin given through a vein and mitomycin C placed directly into the bladder—in 30 people with a specific type of non-muscle-invasive bladder cancer that has a protein called HER2. The goal is to see if this tre…

This phase 2 trial is testing whether two chemotherapy drugs, gemcitabine and docetaxel, given directly into the bladder can treat high-risk bladder cancer that did not respond to standard BCG therapy. About 174 adults will receive weekly treatments for 6 weeks, then monthly for …

This early-stage trial is testing a new drug called RAG-01 in 72 people with a type of bladder cancer that has not responded to standard therapy. The drug uses a small RNA molecule to try to control the cancer. The main goals are to check safety and find the right dose, while als…

This study is testing whether a simple urine test that looks for tumor DNA can help some bladder cancer patients safely have fewer cystoscopy exams. Cystoscopy involves inserting a camera into the bladder and can be uncomfortable. The trial will enroll 56 high-risk patients who h…

This study looks at two common treatments for a type of bladder cancer that keeps coming back: treatments that keep the bladder (like medicine placed directly into the bladder) versus surgery to remove the bladder. The goal is to see which option is better for patients' wallets, …

This study aims to understand the sexual health challenges faced by bladder cancer patients and develop a support program tailored to their needs. Researchers will interview 30 patients to learn about their experiences and preferences for professional help. The goal is to create …